Home

RSS Subscription Links

Clicking on an RSS link below will provide you with raw XML data of our content. If you do not have a compatible reader installed, you will see XML code in your browser - to view our content, paste the feed address into an RSS reader, or use a browser which supports RSS feeds. See below for additional information on RSS.
Press Release
RSS FeedsAll Press Releases
Event Calendar
RSS FeedsAll Calendar Events
SEC Filings
RSS FeedsAll SEC Filings
Additional Information About RSS
Really Simple Syndication (RSS) is an XML-based format for distributing and aggregating Web content (such as news headlines). Using RSS, web content providers can easily create and disseminate news headlines and URLs. To find more information about common RSS Readers, enter the term “RSS Reader” into an internet search engine.
Recommended RSS Readers
Omea Reader, Google Reader, Mozilla Thunderbird
Investor Resources
TNGN(Common Stock)
ExchangeOTC BB (US Dollar)
Price$0.05
Change (%) Stock is Down 0.01 (0.00%)
Volume383,635
Data as of 10/01/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
What's New
September 22, 2014
Tengion Retains Jefferies to Explore Strategic Options for the Company
WINSTON-SALEM, N.C., Sept. 22, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today announced that the Company, with the support of its Board of Directors, is exploring all strategic options to maximize the value of its assets and has retained Jefferies LLC as exclusive financial advisor to assist it with reviewing and structuring potential strategic transactions. "We believe this decision increases our ability to realize the value of our Organ Regene... 
August 13, 2014
Tengion Provides Clinical Update and Reports Second Quarter 2014 Financial Results
WINSTON-SALEM, N.C., Aug. 13, 2014 (GLOBE NEWSWIRE) -- Tengion, Inc. (OTCQB:TNGN), a leader in regenerative medicine, today reported key clinical data along with financial and operating results for the quarter ended June 30, 2014. "Today, we are pleased to announce encouraging six-month interim data for the first five patients implanted in the Phase 1 clinical trial of our Neo-Kidney Augment (NKA) cellular therapy being conducted in Sweden. We believe these early trends support the promising...